European study identifies regulatory research priorities for AI in medicines

18th August 2026

Summary: A European-wide stakeholder study has identified 10 priority areas for regulatory science research into the use of artificial intelligence across the medicines lifecycle. Accuracy and reliability of AI tools emerged as the highest priority, emphasising the need for effective methods to validate and monitor AI and understand its limitations. Other highly ranked areas included data governance, confidentiality and consent, alongside ethics, fairness and bias prevention. The findings, which showed broad consistency across healthcare professionals, patients and consumers, academics, researchers and industry representatives, are intended to help researchers, regulators and funding bodies address important knowledge gaps and develop standards for assessing AI-enabled evidence in medicine development and evaluation.

Link: https://ascpt.onlinelibrary.wiley.com/doi/10.1002/cpt.70400

Back to Recent News